Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Affibody, Alphamab, Astellas, Eisai, Eli Lilly, Huya, Inmagene, Johnson & Johnson, Melior, Pharmaessentia, RDIF, Takeda.